Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the...
Main Authors: | Manuel Gotti, Irene Defrancesco, Mario D’Angelo, Sabrina Basso, Luca Crotto, Alfredo Marinelli, Cristina Maccalli, Vincenzo Iaconianni |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.565236/full |
Similar Items
-
Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma
by: Kristen D. Pawlowski, et al.
Published: (2023-12-01) -
Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
by: Ashley R. Sutherland, et al.
Published: (2020-09-01) -
Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
by: Amy J. Petty, et al.
Published: (2020-03-01) -
Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy
by: Gemma Ferrer-Curriu, et al.
Published: (2023-02-01) -
The role of MSCs and CAR-MSCs in cellular immunotherapy
by: Lun Yan, et al.
Published: (2023-08-01)